相关实验视频

Updated: Jul 25, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

在多发性骨髓瘤中解决治疗阻力机制,通过多组学子克隆分析

Alexandra M Poos^1,2, Nina Prokoph^1,2, Moritz J Przybilla^3,4,5

¹Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.

|June 30, 2023

概括

了解癌症了解癌症

科学领域:

癌症生物学癌症生物学
基因组学就是基因组学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

内瘤异质性构成了重大的临床挑战,特别是在复发性或耐火性多发性髓瘤中.
多药耐药子克隆在多次治疗后会积累,因此需要更深入地了解耐药机制.

研究的目的:

描述多发性骨髓瘤的亚克隆架构和演变.
通过分析亚克隆级别的耐药性机制来确定常见的漏洞和分子标.

主要方法:

整体基因组测序,单细胞 (sc) 转录组学 (scRNA测序) 和单细胞染色质可访问性 (scATAC测序) 的整合.
分析线粒体DNA突变和从15名复发或耐火多发性髓瘤患者的纵向样本.

主要成果:

亚克隆进化的特征和治疗耐药性的多因素性质.
识别先前存在的表观遗传特征,融合的表型适应,以及对抗性有助于产生抗性的子克隆特异性微环境相互作用.

结论:

综合性多组学分析有效地追踪了多药耐药的子克隆.
这种方法有助于识别新的分子标,以克服多发性骨髓瘤治疗阻力.

更多相关视频

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...